Subscribe To

Price Alert Latest News Economic Calendar News

CALT / Calliditas announces acquisition of remaining Genkyotex minority shares

STOCKHOLM, Oct. 7, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company now controls 100% of the share capital of Genkyotex SA ("Genkyotex"), after the completion of a centralized squeeze out offer to all minority shareholders. Genkyotex's lead product candidate, setanaxib, is a first-in-class NOX inhibitor that targets NOX 1 and NOX 4, which are major drivers of fibrogenesis in multiple organs. Read More

Demo Live Account See Partner Details

Content Topics

Invesco

500 Low

Volatility

Etf

Splv

Calliditas

Announces

Acquisition

Remaining

Genkyotex

Minority

Stock

CALT

Posted: Oct 7 2021, 02:21

Author Name: PRNewsWire

CALT News

By PRNewsWire
October 19, 2023

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

STOCKHOLM , Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven ab

By Zacks Investment Research
September 22, 2023

Calliditas Therapeutics AB Sponsored ADR (CALT) Surges 16.1%: Is This an Indication of Further Gains?

Calliditas Therapeutics AB Sponsored ADR (CALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earn

By The Motley Fool
September 21, 2023

Why Shares of Calliditas Therapeutics Are Rising Thursday

Calliditas' lead therapy is Tarpeyo, which has accelerated approval from the FDA to fight a rare autoimmune disease affecting the kidney. The company

By Seeking Alpha
September 3, 2023

Calliditas: Q2 Earnings De-Risk This Biotech Play, 2024 Expected To Be Inflection Point

Calliditas Therapeutics downgrades Tarpeyo sales guidance due to slower-than-expected sales growth and market access challenges. Potential growth driv

By Zacks Investment Research
August 21, 2023

Calliditas (CALT) Up as sNDA for Tarpeyo Gets Priority Review

Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full appr

By Zacks Investment Research
July 6, 2023

Calliditas Therapeutics AB Sponsored ADR (CALT) Moves 12.8% Higher: Will This Strength Last?

Calliditas Therapeutics AB Sponsored ADR (CALT) saw its shares surge in the last session with trading volume being higher than average. The latest tre

By Seeking Alpha
April 12, 2023

Calliditas Therapeutics: Good Long-Term Data Could Boost Tarpeyo Sales

Calliditas Therapeutics recently reported positive long-term data of Tarpeyo (Nefecon/budesonide) in patients with IgA nephropathy. The results confir

By PRNewsWire
March 31, 2023

Calliditas to participate in upcoming investor conferences

STOCKHOLM , March 31, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced its mana

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.